康泰生物(300601.SZ)與艾棣維欣共同研發新冠DNA疫苗
格隆匯2月9日丨康泰生物(300601.SZ)公佈,公司近日與艾棣維欣(蘇州)生物製藥有限公司(“艾棣維欣”)簽署了《戰略合作協議書》。
為加快新冠狀病毒(2019-nCoV)DNA疫苗(“新冠DNA疫苗”)的研發,公司與艾棣維欣簽署擬發揮各自優勢,共同致力於研發新冠DNA疫苗。
雙方組成工作小組,協調各方資源,研究開發新冠DNA疫苗,解決疫苗臨牀前研究、臨牀申報和臨牀試驗中遇到的問題。
艾棣維欣是一傢俱有國際先進水平的疫苗類新藥研發公司,專注於開發基因工程疫苗、DNA疫苗、新型疫苗佐劑等創新技術,在研產品包括重組呼吸道合胞病毒肺炎疫苗、乙肝治療性疫苗、新型冠狀病毒DNA疫苗等。
該協議的簽訂履行,有利於加快推進加快新冠DNA疫苗的研發,為疫情防控積極貢獻科研力量。該協議的簽訂實施,有利於豐富公司的疫苗研發技術、增強公司的疫苗研發實力,不會對公司2020年度的經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.